BIOPROBE DIAGNOSTICS LIMITED

Their core work

Bioprobe Diagnostics is an Irish diagnostic technology SME specialising in rapid environmental testing for waterborne pathogens, with a concentrated focus on Legionella pneumophila — the bacterium responsible for Legionnaires' disease. Their core product is a fast-turnaround detection system designed for use in building water systems, cooling towers, and other high-risk water environments where traditional culture-based testing is too slow. They bring the full development arc from concept to validated product, having taken their Legionella test from a feasibility proof-of-concept through to a funded innovation action. Their value lies in translating microbiological detection science into practical, deployable diagnostic tools for environmental health and water safety compliance.

What they specialise in

How they've shifted over time

Bioprobe's H2020 trajectory is a textbook SME Instrument story: the 2018 Phase 1 grant (€50,000) was a pure feasibility study with no technical keywords attached, indicating early-stage concept validation with limited public disclosure of the technology. By 2020, with Phase 2 funding secured (€844,522), the project is fully articulated around 'human pathogen Legionella environmental testing', showing a sharpened, market-ready focus. There is no meaningful pivot — rather a deepening: they started with a broad water safety concept and committed entirely to Legionella as their lead application, which suggests a deliberate commercial focus rather than research drift.

Bioprobe is moving from R&D validation toward commercial deployment of a specific Legionella diagnostic product, making them a likely candidate for partnerships involving water utilities, facility management companies, or public health agencies needing faster compliance-grade testing.

How they like to work

Bioprobe coordinates every project they participate in, which is typical for a product-focused SME protecting its IP and driving its own commercialisation roadmap. Their consortium is very small — just three unique partners across two countries — suggesting they work with tightly selected, purpose-specific partners rather than broad academic consortia. This profile indicates a company that prefers lean, execution-oriented partnerships over large multi-partner research networks.

Bioprobe has worked with only 3 unique consortium partners across 2 countries, reflecting the compact structure of SME Instrument projects which are by design company-led with minimal consortium overhead. Their geographic collaboration footprint is narrow, likely Ireland plus one other EU country.

What sets them apart

Bioprobe is one of the few Irish SMEs in H2020 with a specific, proprietary environmental diagnostic product targeting a legally regulated waterborne pathogen — Legionella compliance testing is mandatory across the EU under building safety and workplace health regulations, giving their technology a ready-made regulatory market pull. Unlike academic groups working on Legionella research, Bioprobe is commercially oriented, having invested their own project coordination capacity in taking the product through both proof-of-concept and full innovation stages. For a consortium or industry partner, they offer a technology owner with deployment intent, not a research team producing papers.

Highlights from their portfolio

• Bio-LP-1 (IA)
  The largest project (€844,522, 2020-2022) represents a full innovation action to develop and validate a rapid environmental Legionella test — the most commercially significant stage of their development pipeline.
• Bio-LP-1 (SME-1)
  The 2018 feasibility study (€50,000) is notable as the starting point that unlocked Phase 2 funding, demonstrating successful SME Instrument Phase 1 → Phase 2 progression — a competitive outcome achieved by fewer than 10% of Phase 1 applicants.